1. Key Insights 2. PONV Market Overview at a Glance 2.1. Market Share (%) Distribution of Postoperative Nausea and Vomiting (PONV) in 2017 2.2. Market Share (%) Distribution of Postoperative Nausea and Vomiting (PONV) in 2028 3. Postoperative Nausea and Vomiting (PONV): Disease Background and Overview 3.1. Introduction 3.2. Etiology and Risk Factors of Postoperative Nausea and Vomiting (PONV) 3.3. Causes of PONV 3.3.1. Complications of PONV specific to surgery and anesthesia 3.4. Pathophysiological and neurochemical mechanisms of Postoperative Nausea and Vomiting (PONV) 3.4.1. Clinical evidence for the role of volatile anesthetics and opioids 3.4.2. Neural systems for emetic action 3.5. Genetic background of Postoperative Nausea and Vomiting (PONV) 3.6. Risk scores for predicting Postoperative Nausea and Vomiting (PONV) 4. Case Reports 4.1. Case report: Post-operative nausea and vomiting 4.2. Postoperative Complications 5. Epidemiology and Patient Population 5.1. Key Findings 5.2. Epidemiology and Market Methodology 5.3. Total Inpatients Surgeries in the 7MM 5.4. Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM 5.5. United States Epidemiology 5.5.1. Assumptions and Rationale 5.5.2. Total Inpatient Surgery Cases in the United States 5.5.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States 5.5.4. Total Number of Post-Operative Nausea and Vomiting patients in the United States 5.6. EU5 Epidemiology 5.6.1. Germany 5.6.1.1. Assumptions and Rationale 5.6.1.2. Total Inpatient Surgery Cases in Germany 5.6.1.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany 5.6.1.4. Total Number of Post-Operative Nausea and Vomiting patients in Germany 5.6.2. France 5.6.2.1. Assumptions and Rationale 5.6.2.2. Total Inpatient Surgery Cases in France 5.6.2.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France 5.6.2.4. Total Number of Post-Operative Nausea and Vomiting patients in France 5.6.3. Italy 5.6.3.1. Assumptions and Rationale 5.6.3.2. Total Inpatient Surgery Cases in Italy 5.6.3.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy 5.6.3.4. Total Number of Post-Operative Nausea and Vomiting patients in Italy 5.6.4. Spain 5.6.4.1. Assumptions and Rationale 5.6.4.2. Total Inpatient Surgery Cases in Spain 5.6.4.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain 5.6.4.4. Total Number of Post-Operative Nausea and Vomiting patients in Spain 5.6.5. United Kingdom 5.6.5.1. Assumptions and Rationale 5.6.5.2. Total Inpatient Surgery Cases in the UK 5.6.5.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK 5.6.5.4. Total Number of Post-Operative Nausea and Vomiting patients in the UK 5.7. Japan Epidemiology 5.7.1. Assumptions and Rationale 5.7.2. Total Inpatient Surgery Cases in Japan 5.7.3. Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan 5.7.4. Total Number of Post-Operative Nausea and Vomiting patients in Japan 6. Treatment and Management of Postoperative Nausea and Vomiting (PONV) 6.1. First-line antiemetic interventions 6.2. Second-line antiemetic interventions 6.3. Preventive and therapeutic strategies 6.4. Treatment Algorithm 6.5. Treatment Guidelines 6.5.1. ASPAN’S Evidence-Based Clinical Practice Guideline for the Prevention and/or Management of PONV/PDNV 6.5.2. French Society of Anesthesia and Resuscitation Guidelines for Management of PONV 7. Unmet Needs 8. Marketed Drugs 8.1. Aloxi (palonosetron hydrochloride): Helsinn Healthcare 8.1.1. Drug Description 8.1.2. Regulatory Milestones 8.1.3. Other Development Activities 8.1.4. Advantages and Disadvantages 8.1.5. Safety and Efficacy 8.1.6. Product Profile 8.2. Zuplenz (ondansetron): Midatech/Galena Biopharma 8.2.1. Drug Description 8.2.2. Regulatory Milestones 8.2.3. Other Development Activities 8.2.4. Advantages and Disadvantages 8.2.5. Safety and Efficacy 8.2.6. Product Profile 8.3. Emend (aprepitant): Merck 8.3.1. Drug Description 8.3.2. Regulatory Milestones 8.3.3. Other Development Activities 8.3.4. Advantages and Disadvantages 8.3.5. Safety and Efficacy 8.3.6. Product Profile 9. Emerging Drugs 9.1. Barhemsys (APD421): Acacia Pharma 9.1.1. Product Description 9.1.2. Other Developmental Activities 9.1.3. Clinical Development 9.1.4. Clinical trial information 9.1.5. Safety and Efficacy 9.1.6. Product Profile 9.2. CR845 (difelikefalin): Cara Therapeutics 9.2.1. Product Description 9.2.2. Other Developmental Activities: 9.2.3. Clinical Development 9.2.4. Clinical trial information 9.2.5. Safety and Efficacy 9.2.6. Product Profile 9.3. CAM2058: Camurus/Braeburn 9.3.1. Product Description 9.3.2. Other Developmental Activities 9.3.3. Clinical Development 9.3.4. Clinical trial information 9.3.5. Safety and Efficacy 9.3.6. Product Profile 10. Postoperative Nausea and Vomiting (PONV): 7 Major Market Analysis 10.1. Key Findings 10.2. Total Market Size of Postoperative Nausea and Vomiting (PONV) in the 7MM 10.3. PONV Prophylactic Market by Current and Emerging Therapies 10.4. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies. 10.5. Market Size of Postoperative Nausea and Vomiting (PONV) by Therapies in the 7MM 11. Market Outlook: 7MM 11.1. United States Market Size 11.1.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.1.2. PONV Prophylactic Market by Current and Emerging Therapies 11.1.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.1.4. Total PONV Market Size by Therapies 11.2. EU5 11.2.1. Germany 11.2.1.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.2.1.2. PONV Prophylactic Market by Current and Emerging Therapies 11.2.1.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.2.1.4. Total PONV Market Size by Therapies 11.2.2. France 11.2.2.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.2.2.2. PONV Prophylactic Market by Current and Emerging Therapies 11.2.2.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.2.2.4. Total PONV Market Size by Therapies 11.2.3. Italy 11.2.3.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.2.3.2. PONV Prophylactic Market by Current and Emerging Therapies 11.2.3.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.2.3.4. Total PONV Market Size by Therapies 11.2.4. Spain 11.2.4.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.2.4.2. PONV Prophylactic Market by Current and Emerging Therapies 11.2.4.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.2.4.4. Total PONV Market Size by Therapies 11.2.5. United Kingdom 11.2.5.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.2.5.2. PONV Prophylactic Market by Current and Emerging Therapies 11.2.5.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.2.5.4. Total PONV Market Size by Therapies 11.3. Japan 11.3.1. The total Market size of Postoperative Nausea and Vomiting (PONV) 11.3.2. PONV Prophylactic Market by Current and Emerging Therapies 11.3.3. PONV Rescue Treatment Market by Current Treatment and Emerging Therapies 11.3.4. Total PONV Market Size by Therapies 12. Market Drivers 13. Market Barriers 14. SWOT Analysis 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight

Table 1 Candidate genes that affect nausea and vomiting Table 2 Total Inpatient Surgeries in the 7MM (2017–2028) Table 3 Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM (2017-2028) Table 4 Total Inpatient Surgery Cases in the United States (2017-2028) Table 5 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States (2017-2028) Table 6 Total Number of Post-Operative Nausea and Vomiting patients in the United States (2017-2028) Table 7 Total Inpatient Surgery Cases in Germany (2017-2028) Table 8 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany (2017-2028) Table 9 Total Number of Post-Operative Nausea and Vomiting patients in Germany (2017-2028) Table 10 Total Inpatient Surgery Cases in France (2017-2028) Table 11 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France (2017-2028) Table 12 Total Number of Post-Operative Nausea and Vomiting patients in France (2017-2028) Table 13 Total Inpatient Surgery Cases in Italy (2017-2028) Table 14 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy (2017-2028) Table 15 Total Number of Post-Operative Nausea and Vomiting patients in Italy (2017-2028) Table 16 Total Inpatient Surgery Cases in Spain (2017-2028) Table 17 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain (2017-2028) Table 18 Total Number of Post-Operative Nausea and Vomiting patients in Spain (2017-2028) Table 19 Total Inpatient Surgery Cases in the UK (2017-2028) Table 20 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK (2017-2028) Table 21 Total Number of Post-Operative Nausea and Vomiting patients in the UK (2017-2028) Table 22 Total Inpatient Surgery Cases in Japan (2017-2028) Table 23 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan (2017-2028) Table 24 Total Number of Post-Operative Nausea and Vomiting patients in Japan (2017-2028) Table 25 Advantages and side effects of different classes of antiemetic Table 26 Recommended dosages of antiemetic drugs for prophylaxis in adult patients Table 27 Pharmacologic combination therapy for adults and children Table 28 Antiemetic doses for prophylaxis of POV in children Table 29 Antiemetic Doses and Timing for Prevention of Postoperative Nausea and Vomiting in Adult Table 30 Recommendations by the French Society of Anesthesia and Resuscitation Table 31 Barhemsys patents Table 32 Barhemsys, Clinical Trial Description, 2019 Table 33 CR845, Clinical Trial Description, 2019 Table 34 CAM2058, Clinical Trial Description, 2019 Table 35 Market size of PONV by Region in USD Million (2017–2028) Table 36 7MM Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 37 7MM Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 38 7MM Size of PONV by Therapies in USD Million (2017-2028) Table 39 United States Market Size of PONV in USD Million (2017-2028) Table 40 The US Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 41 The US Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 42 The US Market Size of PONV by Therapies in USD Million (2017-2028) Table 43 Germany Market Size of PONV in USD Million (2017-2028) Table 44 Germany Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 45 Germany Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 46 Germany Market Size of PONV by Therapies in USD Million (2017-2028) Table 47 France Market Size of PONV in USD Million (2017-2028) Table 48 France Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 49 France Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 50 France Market Size of PONV by Therapies in USD Million (2017-2028) Table 51 Italy Market Size of PONV in USD Million (2017-2028) Table 52 Italy Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 53 Italy Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 54 Italy Market Size of PONV by Therapies in USD Million (2017-2028) Table 55 Spain Market Size of PONV in USD Million (2017-2028) Table 56 Spain Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 57 Spain Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 58 Spain Market Size of PONV by Therapies in USD Million (2017-2028) Table 59 United Kingdom Market Size of PONV in USD Million (2017-2028) Table 60 UK Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 61 UK Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 62 UK Market Size of PONV by Therapies in USD Million (2017-2028) Table 63 Japan Market Size of PONV in USD Million (2017-2028) Table 64 Japan Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Table 65 Japan Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Table 66 Japan Market Size of PONV by Therapies in USD Million (2017-2028) Figure 1 Causes of vomiting Figure 2 Risk factors associated with PONV Figure 3 Neural pathways and pharmacology of PONV Figure 4 Total Inpatient Surgeries in the 7MM (2017-2028) Figure 5 Total Postoperative Nausea and Vomiting (PONV) Cases in the 7MM (2017-2028) Figure 6 Total Inpatient Surgery Cases in the United States (2017-2028) Figure 7 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the United States (2017-2028) Figure 8 Total Number of Post-Operative Nausea and Vomiting patients in the United States (2017-2028) Figure 9 Total Inpatient Surgery Cases in Germany (2017-2028) Figure 10 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Germany (2017-2028) Figure 11 Total Number of Post-Operative Nausea and Vomiting patients in Germany (2017-2028) Figure 12 Total Inpatient Surgery Cases in France (2017-2028) Figure 13 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in France (2017-2028) Figure 14 Total Number of Post-Operative Nausea and Vomiting patients in France (2017-2028) Figure 15 Total Inpatient Surgery Cases in Italy (2017-2028) Figure 16 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Italy (2017-2028) Figure 17 Total Number of Post-Operative Nausea and Vomiting patients in Italy (2017-2028) Figure 18 Total Inpatient Surgery Cases in Spain (2017-2028) Figure 19 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Spain (2017-2028) Figure 20 Total Number of Post-Operative Nausea and Vomiting patients in Spain (2017-2028) Figure 21 Total Inpatient Surgery Cases in the UK (2017-2028) Figure 22 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in the UK (2017-2028) Figure 23 Total Number of Post-Operative Nausea and Vomiting patients in the UK (2017-2028) Figure 24 Total Inpatient Surgery Cases in Japan (2017-2028) Figure 25 Total Number of Patients taking antiemetic treatment (prophylactic) or not taking anti-emetics in Japan (2017-2028) Figure 26 Total Number of Post-Operative Nausea and Vomiting patients in Japan (2017-2028) Figure 27 Algorithm for the management of PONV Figure 28 Algorithm for PONV prophylaxis Figure 29 Algorithm for PONV prophylaxis Figure 30 Unmet needs of PONV Figure 31 Market size of PONV by Region in USD Million (2017–2028) Figure 32 7MM Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 33 7MM Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 34 Market Size of PONV by Therapies in the 7MM, in USD Million (2017–2028) Figure 35 United States Market Size of PONV in USD Million (2017-2028) Figure 36 The US Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 37 The US Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 38 The US Market Size of PONV by Therapies in USD Million (2017-2028) Figure 39 Germany Market Size of PONV in USD Million (2017-2028) Figure 40 Germany Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 41 Germany Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 42 Germany Market Size of PONV by Therapies in USD Million (2017-2028) Figure 43 France Market Size of PONV in USD Million (2017-2028) Figure 44 France Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 45 France Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 46 France Market Size of PONV by Therapies in USD Million (2017-2028) Figure 47 Italy Market Size of PONV in USD Million (2017-2028) Figure 48 Italy Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 49 Italy Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 50 Italy Market Size of PONV by Therapies in USD Million (2017-2028) Figure 51 Spain Market Size of PONV in USD Million (2017-2028) Figure 52 Spain Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 53 Spain Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 54 Spain Market Size of PONV by Therapies in USD Million (2017-2028) Figure 55 United Kingdom Market Size of PONV in USD Million (2017-2028) Figure 56 UK Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 57 UK Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 58 UK Market Size of PONV by Therapies in USD Million (2017-2028) Figure 59 Japan Market Size of PONV in USD Million (2017-2028) Figure 60 Japan Market Size of PONV Prophylactic Market by Current and Emerging Therapies in USD Million (2017-2028) Figure 61 Japan Market Size of PONV Rescue Treatment by Current Treatment and Emerging Therapies in USD Million (2017-2028) Figure 62 Japan Market Size of PONV by Therapies in USD Million (2017-2028) Figure 63 Market Drivers Figure 64 Market Barriers Figure 65 SWOT analysis

Helsinn Healthcare Midatech/Galena Biopharma Merck Acacia Pharma Cara Therapeutics Camurus/Braeburn